AI assistant
Sending…
Humacyte, Inc. — Director's Dealing 2025
Nov 17, 2025
33410_dirs_2025-11-17_b7c5de86-4821-44c1-b841-62290f5e7ed8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2025-11-16
Reporting Person: Sander Dale A. (CFO and Chief Corp. Deve. Off.)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-16 | Common Stock | A | 311100 | — | Acquired | 313100 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 40600 | Indirect |
Footnotes
F1: The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The first 50% of the RSUs will vest on May 15, 2026, after which the remaining 50% of the RSUs will vest on May 15, 2027.
More from Humacyte, Inc.
Share Issue/Capital Change
2026
May 14
Regulatory Filings
2026
Apr 24
Major Shareholding Notification
2026
Mar 24
Regulatory Filings
2026
Mar 19
Regulatory Filings
2026
Mar 19
Major Shareholding Notification
2026
Jan 9
Capital/Financing Update
2025
Dec 16
Capital/Financing Update
2025
Dec 16
Capital/Financing Update
2025
Dec 15
Regulatory Filings
2025
Dec 15